When drug nanocarriers miss their target: extracellular diffusion and cell uptake are not enough to be effective

Abstract

Biocompatible nanoscale iron carboxylate metal–organic frameworks (nanoMOFs) have already demonstrated their ability to efficiently deliver various therapeutic molecules. The versatility of the synthesis methods and functionalization strategies could further improve their drug carrier potential. However, in oncology, preclinical evaluation still suffers from the lack of relevant models able to mimic the heterogeneity and the microenvironment of human tumors. This may impact the significance of the preclinical data, hindering the clinical translation and drug development process. Motivated by this hurdle, a 3D lung tumor model is herein developed to investigate nanoMOFs, as bare nanoparticles or coated with polyethylene glycol. Loading with doxorubicin, as a model drug, enables the investigation of their penetration capacity and efficacy in the 3D tumor nodule. NanoMOFs carry a large cargo, can diffuse efficiently within the tumor and are capable of significant intracellular penetration. Nevertheless, they prove to be therapeutically ineffective because the loaded drug is sequestrated in the lysosomal compartment and does not reach the nucleus, the doxorubicin sub-cellular target. These results question the in vivo evaluation of these nanoMOFs and call for further optimization to achieve successful drug delivery.